Glaukos Corp (GKOS) Peer Comparison

$180.00

$-1.91 (-1.05%)

As on 28-Aug-2026 13:44EDT

Market cap

$10,906 Mln

Revenue (TTM)

$613 Mln

P/E Ratio

P/B Ratio

16.4

Div. Yield

0 %

Edit

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Bio-Rad Laboratories	Avantor (AVTR)
Market cap ($ Mln)	10,906	12,753	10,222	9,762	9,638
Revenue ($ Mln)	613	1,505	785	2,589	6,561
Net Profit ($ Mln)	-188.05	160.59	41.54	222.40	-578.00
Net Margin (%)	-30.68	10.67	5.29	8.59	-8.81
RoE (%)	-28.10	10.86	1.97	3.04	-10.33
Price to Earnings	--	79.35	251.57	44.47	--
Price-To-Book	16.38	8.41	4.84	1.26	1.68

Income Statement ($ Mln)

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Bio-Rad Laboratories	Avantor (AVTR)
Operating Revenue	612.84	1,504.87	785.10	2,589.30	6,561.10
Cost of Revenue	127.96	483.98	384.30	1,245.50	4,473.00
Gross Profit	393.22	942.44	347.62	1,343.60	2,139.40
Operating Expenses	565.37	833.56	335.50	1,108.90	2,373.70
Operating Profit (EBIT)	-80.49	187.34	65.30	235.00	-285.60
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-192.83	203.83	52.15	350.40	-472.00
Provision for Tax	-4.79	43.24	10.61	128.00	106.00
Profit after Tax (Net Income)	-188.05	160.59	41.54	222.40	-578.00
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Bio-Rad Laboratories	Avantor (AVTR)
Shareholder's Funds	682.49	1,530.77	2,112.03	7,173.90	5,630.20
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	135.71	210.18	705.49	2,116.80	4,583.70
Current Liabilities	102.33	233.78	132.66	961.30	1,382.00
Total Liabilities	893.49	1,826.52	2,949.70	10,576.50	11,794.70

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Bio-Rad Laboratories	Avantor (AVTR)
Non-Current Assets	404.74	630.60	1,749.63	7,231.50	9,133.70
Current Assets	515.78	1,344.12	1,200.55	3,020.50	2,462.20
Total Assets	893.49	1,826.52	2,949.70	10,576.50	11,794.70
Total Debt*	102.84	212.71	690.94	1,203.70	3,697.80
Net Current Assets	413.45	1,110.35	1,067.90	2,059.20	1,080.20

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Bio-Rad Laboratories	Avantor (AVTR)
Cash From Operating Activities	-46.34	238.66	117.42	532.20	623.80
Cash Flow from Investing Activities	-77.61	-404.59	-298.47	-189.70	-130.50
Cash from Financing Activities	11.89	26.53	-15.21	-283.20	-409.40
Net Cash Inflow / Outflow	--	--	--	--	--

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Bio-Rad Laboratories	Avantor (AVTR)
ROCE (%)	-22.53	11.76	1.79	8.98	-5.43
ROE (%)	-28.10	10.86	1.97	3.04	-10.33
ROA (%)	-18.00	7.95	1.36	2.02	-4.08
EBIT Margin (%)	-30.58	13.63	9.87	-5.99	-4.47
Net Margin (%)	-30.68	10.67	5.29	8.59	-8.81
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Bio-Rad Laboratories	Avantor (AVTR)
Revenue Growth (%)	41.55	17.55	16.49	1.37	-1.57
EBIT Growth (%)	-116.42	17.49	920.91	-131.06	-129.16
Net Profit Growth (%)	-102.66	8.72	400.42	-30.32	-184.08
EPS Growth (%)	-96.88	8.12	394.30	-29.66	-184.11
Book Value Growth (%)	-12.65	17.33	2.16	2.19	-9.82

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Bio-Rad Laboratories	Avantor (AVTR)
Price / Earnings	-34.59	68.93	189.42	--	-14.68
Price / Book Value	9.90	8.58	4.40	--	1.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-43.50	53.25	55.90	--	81.94
Market Cap ($ Cr)	--	--	--	--	--

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Bio-Rad Laboratories	Avantor (AVTR)
Debt to Equity	0.00	0.00	0.26	0.11	0.65
Short term debt to equity ratio	0.00	0.01	0.01	0.06	0.01
Current Ratio	5.04	5.75	9.05	3.14	1.78
Quick Ratio	4.46	3.86	7.64	2.33	1.18
Interest Coverage	-38.31	157.91	3.36	8.18	-1.64

	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Bio-Rad Laboratories	Avantor (AVTR)
Debtors to sales (%)	22.67	12.65	20.09	17.06	17.36
Asset Turnover	0.59	0.74	0.26	0.24	0.46
Receivable days	60.95	46.54	72.41	65.39	58.79
Inventory Days	193.84	331.92	146.53	221.09	64.13
Payable days	60.19	26.16	29.05	37.02	58.13
Cash Conversion Cycle	194.60	352.30	189.88	249.46	64.79

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.